Previous 10 | Next 10 |
ANN ARBOR, Mich., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a privately negotiated exchange agreement with two co-managed holders (the “Holders”) of its 4.00% Convertible Senior Subordinated Notes due 2025 (the "Notes")....
– Optimizes organizational structure and operational processes to enable growth as the Company anticipates an inflection post the read-out of the CLEAR Outcomes trial – – Reduces overall workforce by 40 percent and further shifts marketing strate...
Favorable economic news and strong earnings figures helped spark a substantial rally on Thursday, with the S&P 500 scoring its best single-day performance in seven months. Dow component Salesforce.com Inc. (NYSE:CRM) used the tailwind to extend its recent gains, pushing to new 52-week hig...
ANN ARBOR, Mich., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report third quarter 2021 financial results before the open of the U.S. financial markets on Tuesday, November 2, 2021. Following the release, company management will host a webcast an...
ANN ARBOR, Mich., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), the lipid management company, today announced that it will host an investor webinar on the current landscape and future directions in the treatment of elevated cholesterol on Monday, September 13, 2021 at 1:30pm E...
Esperion (ESPR) recently reported mixed Q2 earnings with a beat on EPS and miss on revenue. The earnings were not enough for the market and ESPR continues lower. The company revealed that NEXLETOL and NEXLIZET had a strong quarter with a 67% increase in net revenue and a 28% increase ...
Esperion's sales following its twin therapy approval have been slow to develop. Esperion's products are entering a crowded marketplace with significant price competition. Esperion's potential reward for success is vast. For further details see: Esperion: Hunting Big Game...
Image source: The Motley Fool. Esperion Therapeutics, inc (NASDAQ: ESPR) Q2 2021 Earnings Call Aug 3, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Esperion Therapeutics, inc (ESPR) Q2 2021 Earnings Call Transcrip...
Esperion Therapeutics, Inc. (ESPR) Q2 2021 Earnings Conference Call August 03, 2021 08:00 AM ET Company Participants Ben Church - Investor Relations & Corporate Communications Sheldon Koenig - President & Chief Executive Officer Joanne Foody - Chief Medical Officer Rick Bartram - Chie...
The following slide deck was published by Esperion Therapeutics, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Esperion Therapeutics, Inc. 2021 Q2 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
ANN ARBOR, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2024 financial results before the market opens on Monday, August 12, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financi...
ANN ARBOR, Mich., July 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET. Esperion Therapeutics At Esperion, we discover, develop, and commercialize innovat...
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls &...